Neuland Laboratories Ltd. is a prominent player in the pharmaceutical industry, specializing in the manufacturing and supply of bulk medicines to both domestic and international markets.
The company released its Q3 FY24 results on Monday morning, following a 5.47 percent decline in its stock price.
Despite the current correction, Neuland Laboratories has been a multi-bagger stock. The company has given returns of 380 percent in a year.
Big investors such as Mukul Aggarwal and Vijay Kedia have shown their confidence in Neuland Laboratories by acquiring significant stakes in the company. Mukul Aggarwal holds a 3.12 percent stake, equivalent to 4 lakh equity shares, while Vijay Kedia possesses a 1.25 percent stake, equivalent to 1.6 lakh equity shares.
The company’s market capitalization currently stands at approximately Rs 8,205 crore.
The company has reported robust operating revenue growth of 45.89 percent year-over-year. The company’s operating revenue reached Rs 392.82 crore in Q3 FY24. In the same quarter of last year, it was Rs 269.25.
The company’s net profit also increased by 166.50 percent, from Rs 30.54 crore in Q3 FY23 to Rs 81.39 crore in Q3 FY24.
The company’s customized manufacturing solutions constitute 49 percent, prime API accounts for 25 percent, specialty makes up 20 percent, and other segments contribute 6 percent to the total revenue.
• Neuland Laboratories Limited: A Leading Pharmaceutical Industry Company. The company was established in 1984 and is headquartered in Hyderabad, India. • The company is a leading manufacturer of active pharmaceutical ingredients (APIs). • The company provides comprehensive solutions for the pharmaceutical industry’s chemistry requirements. • The company offers the synthesis of library compounds, the supply of new chemical entities (NCEs) and advanced intermediates, and support for commercial launches. • The company has 1600 well-qualified employees and focuses on strong process chemistry applications in a regulatory-compliant environment. • The company has a remarkable track record of regulatory approvals, with 16 successful US FDA inspections. • The company serves clients across the entire product lifecycle, covering more than 100 APIs across ten therapeutic areas. And operates a state-of-the-art R&D center near Hyderabad, housing around 300 scientists. • • The company has state-of-the-art manufacturing facilities with three world-class plants equipped with advanced technology. • The company is certified by renowned authorities such as the USFDA, EDQM, EMA, PMDA, TGA, and more. • The company maintains a global presence in over 80 countries with over 972 Drug Master Files (DMFs). • The company extends its impact across more than 80 countries, with over 76% of revenues generated from exports.
Management of Neuland Laboratories Limited
Name
Designation
Davuluri Rama Mohan Rao
Executive Chairman
Davuluri Saharsh Rao
Vice Chairman & Managing Director
Davuluri Sucheth Rao
Vice Chairman & CEO
Humayun Dhanrajgir
Ind. Non-Executive Director
Nirmala Murthy
Ind. Non-Executive Director
Homi Rustum Khusrokhan
Ind. Non-Executive Director
Christopher M Cimarusti
Non Executive Director
Bharati Rao
Ind. Non-Executive Director
Parampally Vasudeva Maiya
Ind. Non-Executive Director
Prasad Raghava Menon
Ind. Non-Executive Director
Registered Address of Neuland Laboratories Limited
This is a comprehensive guide to Neuland Laboratories Limited. The above-mentioned information and data are as of February 12, 2024. These figures and projections are based on our research, analysis, company fundamentals and history, experiences, and numerous technical analyses. In addition, we have discussed in depth the share’s prospects and growth potential. Hopefully, these details will be useful in your future investments.
If you’re new to our website and want to stay up-to-date on the newest stock market news, join our Telegram group. If you have any further questions, please leave them in the comments section below. We will gladly address all of your inquiries. If you enjoyed this information, please share it with as many people as possible.
Disclaimer: Dear Readers, we are not authorized by SEBI (Securities and Exchange Board of India). The information provided above is for educational purposes and should not be considered financial advice or stock recommendations. Share price predictions are for reference purposes and are based on positive market indicators. The analysis does not account for uncertainties about future or current market conditions. The author, brokerage firm, or Finreturns.com are not liable for losses resulting from decisions. Finreturns.com advises consulting with certified experts before investment decisions.
[…] Also Read – Neuland Laboratories: Unveiling the Success Behind 380% Multi-bagger Returns […]